Cold is undeniably the new normal for the biopharmaceutical industry. By 2020, greater than half of bestselling drugs will be cold-chain products, most of which are injectable.
With sponsors devoting much of their resources to developing these large molecule products, the demand for pre-filled syringes is escalating rapidly. Many large biopharma companies have their own dedicated automated facilities for assembling and labeling pre-filled syringes for commercial products. However, some lack sufficient capacity to meet both commercial requirements and the growing demands of global clinical trials. Efforts to address both needs can lead to time-consuming bottlenecks as commercial and clinical operations compete for finite internal resources.